Regencell Bioscience Limited(RGC)

POST5.500.000.00%19:30 EDT

5.50-0.04-0.72%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
  GlobeNewswire · 08-03
  Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
- Regencell Bioscience rises 25.2%
  TIPRANKS · 07-09
  Regencell Bioscience rises 25.2%
- Regencell Bioscience Holdings (RGC) Faces DOJ Scrutiny, Is The Stock Too Expensive?
  Simply Wall St. · 07-06
  Regencell Bioscience Holdings (RGC) Faces DOJ Scrutiny, Is The Stock Too Expensive?
- Regencell Bioscience rises 29.6%
  TIPRANKS · 07-02
  Regencell Bioscience rises 29.6%
- Regencell Bioscience falls -13.6%
  TIPRANKS · 06-26
  Regencell Bioscience falls -13.6%
- Regencell Bioscience falls -14.3%
  TIPRANKS · 06-25
  Regencell Bioscience falls -14.3%
- S&P 500 Futures Decline In Premarket Trading; Primoris Services, Tower Semiconductor Lag
  Dow Jones · 06-23
  S&P 500 Futures Decline In Premarket Trading; Primoris Services, Tower Semiconductor Lag
- Regencell Bioscience falls -14.7%
  TIPRANKS · 06-18
  Regencell Bioscience falls -14.7%
- Regencell Bioscience Holdings (RGC) Stock Valuation After Securities Class Action Raises Fresh Concerns
  Simply Wall St. · 06-16
  Regencell Bioscience Holdings (RGC) Stock Valuation After Securities Class Action Raises Fresh Concerns
- Regencell Bioscience Holdings (RGC) Is Down 11.5% After DOJ Subpoena Spurs Class Actions Over Alleged Misstatements – Has The Bull Case Changed?
  Simply Wall St. · 06-10
  Regencell Bioscience Holdings (RGC) Is Down 11.5% After DOJ Subpoena Spurs Class Actions Over Alleged Misstatements – Has The Bull Case Changed?
- A Look At Regencell Bioscience Holdings (RGC) Valuation After DOJ Subpoena And Shareholder Class Actions
  Simply Wall St. · 06-05
  A Look At Regencell Bioscience Holdings (RGC) Valuation After DOJ Subpoena And Shareholder Class Actions
- RGC Resources Establishes New $15 Million Term Loan
  TIPRANKS · 06-05
  RGC Resources Establishes New $15 Million Term Loan
- Zscaler, AutoZone, And Regencell Are Among Top 10 Large-Cap Losers Last Week (May 25-May 29): Are The Others In Your Portfolio?
  Benzinga · 05-31
  Zscaler, AutoZone, And Regencell Are Among Top 10 Large-Cap Losers Last Week (May 25-May 29): Are The Others In Your Portfolio?
- Regencell Bioscience closes USD 20 million registered direct share offering
  Reuters · 05-22
  Regencell Bioscience closes USD 20 million registered direct share offering
- Regencell Bioscience faces shareholder class action over alleged stock manipulation risks
  Reuters · 05-21
  Regencell Bioscience faces shareholder class action over alleged stock manipulation risks
- RGC Resources Balances Earnings Strength and New Risks
  TIPRANKS · 05-20
  RGC Resources Balances Earnings Strength and New Risks
- Regencell Bioscience prices 985,222-share registered direct offering at $20.30 per share
  Reuters · 05-19
  Regencell Bioscience prices 985,222-share registered direct offering at $20.30 per share
- Regencell FY26 H1 net loss widens 187% to $5.3 million
  Reuters · 05-09
  Regencell FY26 H1 net loss widens 187% to $5.3 million
- Regencell Bioscience Holdings Faces Federal Securities Lawsuit Over Alleged Market Manipulation Disclosures
  TIPRANKS · 05-07
  Regencell Bioscience Holdings Faces Federal Securities Lawsuit Over Alleged Market Manipulation Disclosures
- Regencell Bioscience Holdings Faces Investor Lawsuit Alleging Securities Fraud Tied to DOJ Investigation and Stock Volatility
  TIPRANKS · 05-02
  Regencell Bioscience Holdings Faces Investor Lawsuit Alleging Securities Fraud Tied to DOJ Investigation and Stock Volatility
Company Profile
Company Name
Regencell Bioscience Limited
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.regencellbioscience.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
- 2025-10-31
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-10-25
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2023-10-28
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2022-10-31
  Annual Report
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2022-07-26
  Beneficial Ownership Change
  SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
  SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
- 2022-05-16
  Beneficial Ownership Change
  SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
  SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
- 2022-04-04
  Beneficial Ownership Change
  SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
  SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
- 2021-12-30
  Beneficial Ownership Change
  SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
  SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
- 2021-12-15
  Beneficial Ownership Change
  SC 13G - Statement of acquisition of beneficial ownership by individuals
  SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2021-07-13
  Correspondence
  CORRESP [Cover] - Correspondence
  CORRESP [Cover] - Correspondence
- 2021-07-13
  Correspondence
  CORRESP [Cover] - Correspondence
  CORRESP [Cover] - Correspondence
- 2021-07-08
  [Supp]Public Prospectus
  FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2021-06-30
  [Supp]Public Prospectus
  FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2021-06-23
  [Amend]Public Prospectus
  F-1/A [Amend] - Registration statement for certain foreign private issuers
  F-1/A [Amend] - Registration statement for certain foreign private issuers
- 2021-06-22
  Correspondence
  CORRESP [Cover] - Correspondence
  CORRESP [Cover] - Correspondence

1D
5D
Day
Week
Month

Loading ...

High

5.58

Open

5.53

Volume%

0.39

Low

5.40

5.54

T/O Rate

0.33%

To The Moon

Regencell Bioscience Limited(RGC)

Company Profile

Most Discussed